Affimed N.V. (AFMD) shares were rising 15.58% to exchange at $5.12 in pre-market at last check subsequent to introducing refreshed clinical consequences of a review in a significant event. AFMD stock lost – 6.14% to close Friday’s session at $4.43.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free.
Where AFMD has presented the data?
Affimed (AFMD) provided an update on the Company’s lead intrinsic cell engager (ICE) AFM13 precomplexed with cord blood-derived natural killer (cbNK) cells, which is still being investigated. AFM13 is now being studied in patients with CD30-positive backsliding or obstinate Hodgkin and non-Hodgkin lymphomas at The University of Texas MD Anderson Cancer Center in a stage 1/2 trial.
Yago Nieto, M.D., Ph.D., professor of Stem Cell Transplantation and Cellular Therapy at MD Anderson, is leading the expert-led evaluation. After two patterns of therapy, AFMD concentrates on exhibiting a 100 percent objective reaction rate (ORR) and a 62 percent complete reaction rate (CR) at the recommended phase 2 dosage (RP2D) in 13 patients. The findings were presented at the American Association for Cancer Research (AACR) Annual Meeting 2022 at a Clinical Plenary Session on cell immunotherapies, and they were also discussed in an AACR public interview earlier today.
How well do the clinical studies hold up?
The treatment was well tolerated, with few side effects other than the standard myelosuppression caused by the previous lymphodepleting chemotherapy. There were no signs of cytokine release abnormality, insusceptible effector cell-related neurotoxicity, or joining versus having an infection. There were six mixture-related reactions in 110 imbuements (5.4 percent) of AFM13 alone, but no responses to AFM13-precomplexed cbNK.
What has AFMD shared?
The information provided by Affimed (AFMD) is really comforting, as all of the patients on the preliminary were resistant to all treatment options. Still, the combination of AFM13 with precomplexed NK cells resulted in a 100% response rate and a 62 percent complete reaction rate. AFMD also wants to see an extension of responses from incomplete to complete reactions with the following cycle, so they’ve changed the review to allow patients to undergo more cycles, which might help them improve their adequacy. The executives of AFMD confirmed that, as far as anybody is concerned, this is the highest response rate reported in Hodgkin Lymphoma patients with treatment-resistant illness in a long time.